Full Press Release Details
Inspira in High-Level Government Talks to Advance
National Integration of
the ART100 and Establish a Global Distribution Framework
RA'ANANA, Israel, July 7, 2025 -- Inspira Technologies OXY B.H.N.
Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer
in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health
authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system
as a foundational component of the national emergency infrastructure and to establish a global distribution framework.
The meeting, scheduled for July 8, 2025, is intended to define the
key terms and roadmap for this strategic collaboration. These advanced discussions were initiated following a direct invitation from the
government of the health authority, which is actively seeking to secure next-generation medical technologies and enhance national emergency
The government involved is recognized for its extensive commercial
ties and diplomatic channels spanning the entire international community. Accordingly, the agenda will also feature the discussion relating
to the establishment of a global distribution framework that leverages these unique capabilities with the aim to accelerate and increase
the profitability of the $22.5 million purchase order received by Inspira, as announced on July 2, 2025.
Dagi Ben-Noon, CEO of Inspira Technologies, stated: "Engaging
in strategic dialogue with national leadership is an important milestone for us and that it reflects the growing recognition that the
ART100 is more than a medical device, but rather a vital tool for national preparedness. In parallel, we intend to leverage the government's
international reach to build a global distribution engine that is intended to maximize the profitability of our recent deal and those
This high-level discussions marks a significant validation and acceleration
of Inspira's stated strategy, signaling a fundamental shift from regional commercial deals to global, government-level partnerships.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing
in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. Food and Drug Administration -cleared
INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures
outside the U.S and serves as a foundation for the development of the INSPIRA ART500 - a next-generation system designed to deliver
oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA , a proprietary
blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic
streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and
MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including
consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of
the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected
timing and nature of the meeting with the government health authority with which it is holding discussions, including the intended role
of the ART100 system in the national emergency infrastructure and global distribution framework vision, the anticipated increased profitability
of the Company should it be able to leverage its recent purchase order, the belief that engaging in strategic dialogue with national leadership
is an important milestone for the Company and that it reflects the growing recognition that the ART100 is a vital tool for national preparedness,
the Company's intention to leverage the government's international reach to build a global distribution engine that will maximize
the profitability of the Company's recent purchase order, and the belief that these discussions mark a significant validation and
acceleration of the Company's stated strategy, signaling a fundamental shift from regional commercial deals to global, government-level
partnerships. These forward-looking statements and their implications are based solely on the current expectations of the Company's management
and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors"
in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission
(the "SEC"), which is available on the SEC's website at www.sec.gov.
Inspira Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485